How I treat pregnancy-related venous thromboembolism

Blood

Volumn 118, Issue 20, 2011, Pages 5394-5400

  Middeldorp, Saskia ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; DANAPAROID; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; THROMBIN INHIBITOR;

ARTICLE; BREAST FEEDING; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSPNEA; GESTATIONAL AGE; HUMAN; HYPERSENSITIVITY REACTION; INJECTION SITE CONTUSION; LUNG EMBOLISM; MATERNAL CARE; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; RISK ASSESSMENT; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

EID: 81555196381     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-306589     Document Type: Article

References (55)

1. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194(5):1311-1315.
2. Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance: United States, 1991-1999. MMWR Surveill Summ. 2003;52(2):1-8.
3. Rosfors S, Noren A, Hjertberg R, Persson L, Lillthors K, Torngren S. A 16-year haemodynamic follow-up of women with pregnancy-related medically treated iliofemoral deep venous thrombosis. Eur J Vasc Endovasc Surg. 2001;22(5):448-455. (Pubitemid 33085555)
4. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143(10):697-706.
5. Jacobsen AF, Skjeldestad FE, Sandset PM. Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost. 2008;6(6):905-912. (Pubitemid 351689910)
6. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692-699. (Pubitemid 46563566)
7. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008;6(4):632-637. (Pubitemid 351404930)
8. Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv. 1999;54(4):265-271. (Pubitemid 29162858)
9. Chan WS, Lee A, Spencer FA, et al. Predicting deep venous thrombosis in pregnancy: out in "LEFt" field? Ann Intern Med. 2009;151(2):85-92.
10. Chan WS, Lee A, Spencer FA, et al. D-dimer testing in pregnant patients: towards determining the next "level" in the diagnosis of DVT. J Thromb Haemost. 2010;8(5):1004-1011.
11. Nijkeuter M, Ginsberg JS, Huisman MV. Diagnosis of deep vein thrombosis and pulmonary embolism in pregnancy: a systematic review. J Thromb Haemost. 2006;4(3):496-500.
12. Ginsberg JS, Hirsh J, Rainbow AJ, Coates G. Risks to the fetus of radiologic procedures used in the diagnosis of maternal venous thromboembolic disease. Thromb Haemost. 1989;61(2):189-196. (Pubitemid 19124387)
13. Nijkeuter M, Geleijns J, de Roos A, Meinders AE, Huisman MV. Diagnosing pulmonary embolism in pregnancy: rationalizing fetal radiation exposure in radiological procedures. J Thromb Haemost. 2004;2(10):1857-1858. (Pubitemid 40192730)
14. van Dongen CJ, MacGillavry MR, Prins MH. Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev. 2005;CD003074.
15. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):454S-545S. (Pubitemid 351892971)
16. Ferretti G, Bria E, Giannarelli D, et al. Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants? Chest. 2006;130(6):1808-1816. (Pubitemid 46033438)
17. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153. (Pubitemid 36818784)
18. Voke J, Keidan J, Pavord S, Spencer NH, Hunt BJ. The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey. Br J Haematol. 2007;139(4):545-558. (Pubitemid 350063843)
19. Knight M. Antenatal pulmonary embolism: risk factors, management and outcomes. Br J Obstet Gynaecol. 2008;115(4):453-461. (Pubitemid 351225139)
20. Crowther MA, Spitzer K, Julian J, et al. Pharma-cokinetic profile of a low-molecular weight heparin (reviparin) in pregnant patients: a prospective cohort study. Thromb Res. 2000;98(2):133-138. (Pubitemid 30122301)
21. Rodie VA, Thomson AJ, Stewart FM, Quinn AJ, Walker ID, Greer IA. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series. Br J Obstet Gynaecol. 2002;109(9):1020-1024. (Pubitemid 35279133)
22. Jacobsen AF, Qvigstad E, Sandset PM. Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. Br J Obstet Gynaecol. 2003;110(2):139-144. (Pubitemid 36263109)
23. Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain the rapeutic levels of anticoagulation. Am J Obstet Gynecol. 2004;191(3):1024-1029. (Pubitemid 39298153)
24. Rey E, Rivard GE. Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet. 2000;71(1):19-24.
25. Smith MP, Norris LA, Steer PJ, Savidge GF, Bonnar J. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol. 2004;190(2):495-501. (Pubitemid 38249251)
26. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):844S-886S. (Pubitemid 351892978)
27. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106(2):401-407. (Pubitemid 40981229)
28. van Driel D, Wesseling J, Sauer PJ, Touwen BC, van der Veer, Heymans HS. Teratogen update: fetal effects after in utero exposure to coumarins overview of cases, follow-up findings, and pathogenesis. Teratology. 2002;66(3):127-140. (Pubitemid 34977008)
29. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med. 2000;160(2):191-196. (Pubitemid 30054338)
30. Schaefer C, Hannemann D, Meister R, et al. Vitamin K antagonists and pregnancy outcome: a multi-centre prospective study. Thromb Haemost. 2006;95(6):949-957. (Pubitemid 43940752)
31. Wesseling J, van Driel D, Smrkovsky M, et al. Neurological outcome in school-age children after in utero exposure to coumarins. Early Hum Dev. 2001;63(2):83-95. (Pubitemid 32530072)
32. Wesseling J, van Driel D, Heymans HS, et al. Coumarins during pregnancy: long-term effects on growth and development of school-age children. Thromb Haemost. 2001;85(4):609-613. (Pubitemid 32293694)
33. Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost. 2005;93(1):63-69. (Pubitemid 40124256)
34. Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N Engl J Med. 2004;350(18):1914-1915.
35. te Raa GD, Ribbert LS, Snijder RJ, Biesma DH. Treatment options in massive pulmonary embolism during pregnancy: a case-report and review of literature. Thromb Res. 2009;124(1):1-5.
36. Holden EL, Ranu H, Sheth A, Shannon MS, Madden BP. Thrombolysis for massive pulmonary embolism in pregnancy: a report of three cases and follow up over a two year period. Thromb Res. 2011;127(1):58-59.
37. Lepercq J, Conard J, Borel-Derlon A, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br J Obstet Gynaecol. 2001;108(11):1134-1140. (Pubitemid 33052475)
38. Bauersachs RM, Dudenhausen J, Faridi A, et al. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost. 2007;98(6):1237-1245. (Pubitemid 350239095)
39. Maslovitz S, Many A, Landsberg JA, Varon D, Lessing JB, Kupferminc MJ. The safety of low molecular weight heparin therapy during labor. J Matern Fetal Neonatal Med. 2005;17(1):39-43. (Pubitemid 40515942)
40. Kominiarek MA, Angelopoulos SM, Shapiro NL, Studee L, Nutescu EA, Hibbard JU. Low-molecular- weight heparin in pregnancy: peripartum bleeding complications. J Perinatol. 2007;27(6):329-334. (Pubitemid 46863128)
41. Roshani S, Cohn DM, Stehouwer AC, et al. Risk of early postpartum hemorrhage in women receiving therapeutic doses of low-molecular-weight heparin. BMJ Open. 2011;1:e000257. doi 10.1136/bmjopen-2011-00257.
42. Butwick AJ, Carvalho B. Neuraxial anesthesia in obstetric patients receiving anticoagulant and antithrombotic drugs. Int J Obstet Anesth. 2010;19(2):193-201.
43. Bank I, Libourel EJ, Middeldorp S, van der Meer J, Buller HR. High rate of skin complications due to low-molecular-weight heparins in pregnant women. J Thromb Haemost. 2003;1(4):859-861.
44. Wutschert R, Piletta P, Bounameaux H. Adverse skin reactions to low molecular weight heparins: frequency, management and prevention. Drug Saf. 1999;20(6):515-525. (Pubitemid 29296597)
45. Schindewolf M, Kroll H, Ackermann H, et al. Heparin-induced non-necrotizing skin lesions: rarely associated with heparin-induced thrombocytopenia. J Thromb Haemost. 2010;8(7):1486-1491.
46. Verdonkschot AEM, Vasmel WLE, Middeldorp S, Van der Schoot JT. Skin reactions due to low-molecular-weight heparin in pregnancy: a strategic dilemma. Arch Gynecol Obstet. 2005;271(2):163-165. (Pubitemid 40476251)
47. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):340S-380S. (Pubitemid 351892970)
48. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol. 1993;168(4):1265-1270. (Pubitemid 23122178)
49. Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost. 2002;87(2):182-186. (Pubitemid 34139851)
50. Carlin AJ, Farquharson RG, Quenby SM, Topping J, Fraser WD. Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. Hum Reprod. 2004;19(5):1211-1214. (Pubitemid 38618507)
51. Boneu B, Navarro C, Cambus JP, et al. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU/mL) delivered for 10 days at therapeutic dose. Thromb Haemost. 1998;79(2):338-341. (Pubitemid 28065881)
52. Milford W, Chadha Y, Lust K. Use of a retrievable inferior vena cava filter in term pregnancy: case report and review of literature. Aust N Z J Obstet Gynaecol. 2009;49(3):331-333.
53. McConville RM, Kennedy PT, Collins AJ, Ellis PK. Failed retrieval of an inferior vena cava filter during pregnancy because of filter tilt: report of two cases. Cardiovasc Intervent Radiol. 2009;32(1):174-177.
54. Houwert-de Jong M, Gerards LJ, Tetteroo-Tempelman CA, de Wolff FA. May mothers taking acenocoumarol breast feed their infants? Eur J Clin Pharmacol. 1981;21(1):61-64. (Pubitemid 12237831)
55. Clark SL, Porter TF, West FG. Coumarin derivatives and breast-feeding. Obstet Gynecol. 2000;95(6):938-940.